Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca’s Outlicensing Tactics Make It Top Dealmaker

Executive Summary

Datamonitor report highlights big pharma’s licensing trends from last five years, and finds UK firm top on numbers of deals, but Merck & Co put up most money.

You may also be interested in...



Deal Watch: Castle Creek Likes Partner Fibrocell Enough To Buy It

Dermatology-focused regenerative medicine firm Fibrocell has been reviewing strategic opportunities for more than a year; April’s FCX-007 license deal with Castle Creek results in buyout.

Nektar Pins Falling Cancer Response Rate On Manufacturing Problem

A post-hoc analysis linked “physical differences” in two lots of Nektar’s drug to lower efficacy when given in combination with Bristol-Myers Squibb’s Opdivo. Nektar’s share price tumbled following the update.

Regeneron And Teva's Fasinumab Crosses One Threshold; More Remain

The companies reported positive Phase III data testing the nerve growth factor inhibitor in patients with chronic pain, but the efficacy appears modest and safety will remain a question until long-term Phase III data read out. The companies are focused on a lower 1 mg dose.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

OM004559

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel